Efficacy of Symprove Probiotics in Coeliac Disease

  • Research type

    Research Study

  • Full title

    A Proof-of-Concept Study to Assess the Efficacy of Symprove Probiotics in Managing Persistent Gastrointestinal Symptoms in Adult Coeliac Disease Patients in Histological Remission

  • IRAS ID

    354291

  • Contact name

    David Sanders

  • Contact email

    david.sanders1@nhs.net

  • Sponsor organisation

    Sheffield Teaching Hospitals NHS FT

  • Clinicaltrials.gov Identifier

    NCT07360106

  • Duration of Study in the UK

    1 years, 0 months, 29 days

  • Research summary

    Coeliac disease (CD) is a lifelong autoimmune condition where eating gluten (a protein found in wheat, barley, and rye) causes damage to the small intestine. It affects around 1 in 100 people. Most individuals feel better and their gut heals after switching to a strict gluten-free diet. However, up to 1 in 5 people with coeliac disease continue to experience unpleasant gut symptoms—such as bloating, pain, and diarrhoea—despite following the diet and having a healed intestine. These ongoing symptoms can be very distressing and impact daily life.

    This project is a single-centre, uncontrolled preliminary (proof-of-concept) study with a target sample size of 24 participants. It investigates whether a food supplement called Symprove, a probiotic drink containing live “good” bacteria, can help relieve ongoing gut symptoms in people with coeliac disease who are in remission.
    Scientists believe that in some people with coeliac disease, the community of bacteria in the gut (called the microbiota) becomes unbalanced, even after going gluten-free. This imbalance—known as dysbiosis—may lead to inflammation, irritation, and symptoms similar to irritable bowel syndrome (IBS). The aim of this study is to test whether Symprove can help correct this imbalance and reduce symptoms.

    What taking part will involve (from a patient perspective)
    If you take part, you will:
    • Take Symprove every day at home (70 mL orally once daily) for 3 months, with the option of a fourth month if all study assessments are completed.
    • Complete symptom and quality-of-life questionnaires at the start and then monthly during the study.
    • Provide stool samples (collected at home using a kit) at the start and again at the end, so researchers can measure gut bacteria and see whether it changes over time.

    Overall, each participant is expected to be involved for up to 4 months in total.

    The key questions the study hopes to answer
    1. Can Symprove reduce gut symptoms in people with coeliac disease who are in remission?
    2. Does it work by restoring a healthy balance of gut bacteria?
    3. Are people with more severe imbalance (dysbiosis) more likely to have symptoms?

    What the results could lead to next
    Because this is uncontrolled and preliminary, it is designed to provide early signals about whether symptoms and gut bacteria improve over time with Symprove, and to help plan what to do next. Depending on the findings, potential next steps could include larger studies (possibly in more than one centre) and a future study that compares Symprove to a control (such as a placebo) to test effectiveness more definitively, and/or refining which patients are most likely to benefit (for example, those with more marked dysbiosis).
    .

  • REC name

    East Midlands - Nottingham 1 Research Ethics Committee

  • REC reference

    25/EM/0281

  • Date of REC Opinion

    11 Dec 2025

  • REC opinion

    Favourable Opinion